

First Hit

End of Result Set

☐ **Generate Collection** **Print**

L22: Entry 1 of 1

File: DWPI

Sep 21, 2000

DERWENT-ACC-NO: 2000-594407

DERWENT-WEEK: 200056

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New coordination compound comprising manganese, glutamic acid and vitamin C, with hypoglycemic and diuretic activity, useful for treating kidney disease and diabetes

INVENTOR: AKBAROV, A B; ARIPKHODZHAEVA, F A

PATENT-ASSIGNEE:

ASSIGNEE

CODE

AKBAROV A B

AKBAI

PRIORITY-DATA: 1999UZ-0000160 (March 15, 1999)

Search Selected**Search ALL****Clear**

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>WO 200054784 A1</u>	September 21, 2000	E	017	A61K033/32

DESIGNATED-STATES: IN US UZ AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 200054784A1	March 16, 1999	1999WO-UZ00001	

INT-CL (IPC): A61 K 31/375; A61 K 33/32; A61 P 13/12

ABSTRACTED-PUB-NO: WO 200054784A

BASIC-ABSTRACT:

NOVELTY - A new coordination complex comprising manganese, glutamic acid and vitamin C has both hypoglycemic and diuretic activity, and is useful for treating kidney disease and diabetes.

DETAILED DESCRIPTION - A coordination compound comprising manganese, glutamic acid and vitamin C, of formula $C_{11}H_{15}MnO_{10}N.nH_2O$ (I) ($n = 1-3$) is new.

An INDEPENDENT CLAIM is included for the preparation of (I).

ACTIVITY - Hypoglycemic; diuretic.

Acute renal failure was produced in rats by intramuscular injection of 50% aqueous glycerine (10 mg/kg). After 24 hours, one group (A) was injected with (I) (10 mg/kg) for 10 days, while the control group (B) received water for injection. Tests were carried out on urine and blood, e.g. blood levels of ammonia on days 1 and 10 for (A) and (B) were 37.90 plus or minus 1.22 and 16.3 plus or minus 0.52 mmol/l, and 41.6 plus or minus 1.58 and 39.61 plus or minus 1.09 mmol/l respectively; compared with 17.9 plus or minus 1.34 mmol/l for an intact, untreated control group.

The volume of urine excreted during the first 24 hours after dosing was 5.23 plus or minus 0.78 ml for group (A) compared with 2.43 plus or minus 0.70 ml for (B), and on day 10 the diuresis index was 2.5 times higher for (A) than (B). For an intact, untreated group, the volume of urine was 4.21 plus or minus 0.59 ml/day.

MECHANISM OF ACTION - None given.

USE - For treating kidney disease, e.g. for removal of uremic toxins, for increasing glomerular filtration and minute diuresis in treatment of acute and chronic forms of kidney disease; and for reduction of blood glucose level in treatment of acute and chronic hyperglycemia, also diabetes connected with pancreas dysfunction.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: NEW COORDINATE COMPOUND COMPRISE MANGANESE GLUTAMIC ACID VITAMIN
DIURETIC ACTIVE USEFUL TREAT KIDNEY DISEASE DIABETES

DERWENT-CLASS: B05

CPI-CODES: B03-F; B05-A03A; B10-B02E; B14-N10; B14-N13; B14-S04;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

A425 A950 A960 C108 C550 C710 C801 C802 C803 C804
C805 C807 F012 F013 F014 F015 F017 F113 H100 H181
H404 H422 H482 J012 J172 J521 L942 M280 M312 M313
M321 M332 M343 M349 M373 M381 M391 M411 M510 M520
M521 M530 M540 M630 M710 M720 M800 M904 M905 N104
N422 N513 N514 P722 P723 P816

Specific Compounds

A2IP6T A2IP6N A2IP6P

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-177568